Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GreenLeaf Genetics was a prominent agricultural biotechnology joint venture established in 2006 between Syngenta and Pioneer Hi-Bred, a subsidiary of DuPont. The company was created to facilitate the out-licensing of elite corn and soybean germplasm and advanced biotech traits to independent seed companies across North America. Its portfolio included significant technologies such as the Agrisure and Herculex trait families, which provide insect resistance and herbicide tolerance. In 2010, Syngenta acquired DuPont's 50% stake to become the sole owner of the entity. This acquisition allowed Syngenta to fully integrate the licensing business into its global seeds strategy. GreenLeaf Genetics remains a key historical example of strategic collaboration in the ag-biotech sector.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GreenLeaf Genetics.